NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This contract opportunity invites investigators to submit applications aimed at advancing the development and translation of innovative diagnostic and therapeutic technologies targeting brain disorders and addiction as part of the NIH BRAIN and HEAL initiatives. The focus is on progressing new devices through technology development and optimization to overcome critical challenges identified in initial proof-of-concept studies, ultimately preparing these technologies for first-in-human clinical trials. The program supports activities that enable regulatory readiness and facilitate the translation of next-generation devices for clinical use. The solicitation, titled "NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices," prohibits clinical trials within the award and emphasizes preparation steps leading to human testing. Managed by the National Institutes of Health under the Department of Health and Human Services, this funding opportunity was posted on February 27, 2026. Interested parties are encouraged to contact the NIBIB program officers via the provided email for further information and application guidance.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This Notice of Funding Opportunity (NOFO) is to encourage applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) and The Helping to End Addiction Long-term (HEAL) Initiatives. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.
